Wells Fargo’s Asterias Biotherapeutics Warrants AST.WS Stock Holding History
Bought
Maintained
Sold
Wells Fargo's AST.WS Position: Q3 2017 in Review
Wells Fargo sold out of Asterias Biotherapeutics Warrants (AST.WS) in Q3 2017, closing a stake of 76 shares.
Wells Fargo first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $0 in Q2 2017. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.
- Wells Fargo reported no remaining Asterias Biotherapeutics Warrants position as of Q3 2017 after selling out during the quarter.
- Wells Fargo sold 76 Asterias Biotherapeutics Warrants shares in Q3 2017.
- Wells Fargo first reported a position in Asterias Biotherapeutics Warrants in Q2 2016 and held it in 5 quarters.
- Wells Fargo's Asterias Biotherapeutics Warrants position peaked at $0 in Q2 2017.
- 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Warrants as of Q3 2017.
Based on Wells Fargo's 13F filing for Q3 2017, filed 9 Nov 2017.